As deeper mouse model mimics original human cancer biology as more satisfactory experimental drug testing would predict it''s efficacy in clinic. New mouse models of breast cancer and leukemic lymphoma are maintained in conventional (non Specific Pathogen Free) conditions to reproduce multifaceted process of cancer development as consequences of genetic predisposition and chronic inflammation interplay. Lobular and ductal mammary lesions occur in the mice naturally at multiple primary localizations mimicking corresponding preneoplastic and neoplastic human diseases. Hence, these models are clearly more adequate to familial set of human breast cancer than standard SPF models. Author''s mouse models, reproducing both human cancer itself and some concurrent pathological conditions are recommended for use in preclinical research as concomitant chronic pathologies in human patients may impede anticancer drug efficacy. Indeed, both benefit and non-benefit sets of recipients were revealed during testing efficacy of interleukin-2 immunotherapy and lectin target chemotherapy using these mice. Conclusion: selection procedure for cancer patients before therapy application should be developed.